Galavit

Clinical trials

Two clinical trials with Galavit have been conducted on non-cancer patients and published in Russian. For this summary only their English abstracts could be used. Larina et al examined the immune status of 28 patients with cicatricial stenosis of the trachea. 12 Galavit given pre- and postoperatively increased the level of T-helper (CD4+) and natural killer cells (CD16+) and induced the phagocyte activity of neutrophils.

Maev et al examined microcirculatory disturbances with Doppler laser flowmetry in 95 patients with chronic gastric erosions (CGE). 13 Treatment of the erosions with triad therapy eradicated the erosions in 80%. Additional therapy with Galavit showed a more effective restoration of the blood flow.

Pre-clinical studies

One pre-clinical study 11 with albino mice (10 verum, 10 control) examined the effect of Galavit (8 mg/kg injected intramuscularly from day four of disease) on interleukin-1 (IL-1) and tumour necrosis factor (TNF) production after infective doses of two types of rickettsial infection via intraperioneal infection. In animals infected with spotted fever, clinical manifestation was reduced by two days and clinical signs were less pronounced and absent in 20% of them. In animals infected with scrub typhus the clinical manifestation was reduced in addition, and mortality was reduced by 50%. In both groups IL-1 and TNF were decreased.